Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$351 Mln
Revenue (TTM)
$-- Mln
Net Profit (TTM)
$-- Mln
ROE
0.1 %
ROCE
-- %
P/E Ratio
8.5
P/B Ratio
1
Industry P/E
--
EV/EBITDA
2
Div. Yield
0 %
Debt to Equity
0.1
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
24,180,904
CFO
$-931.64 Mln
EBITDA
$-1,200.80 Mln
Net Profit
$117.63 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
PureTech Health PLC (PRTC)
| -9.9 | -10.6 | -9.9 | -24.2 | -19.7 | -24.0 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
PureTech Health PLC (PRTC)
| -9.9 | -34.3 | -11.7 | -13.8 | -31.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
PureTech Health PLC (PRTC)
|
15.0 | 350.6 | 4.8 | 53.5 | -- | 12.2 | 8.5 | 1.0 |
| 3.4 | 311.8 | 73.2 | -67.8 | -55.3 | -65.5 | -- | 4.1 | |
| 20.5 | 1,088.5 | 0.5 | -147.4 | -29,734.7 | -150.3 | -- | 6.4 | |
| 29.8 | 1,904.4 | 1,112.2 | 320.9 | -17.8 | 10.5 | 5.2 | 0.5 | |
| 15.2 | 2,582.6 | 550.0 | 458.1 | -3.3 | 45.9 | 5.4 | 1.9 | |
| 15.8 | 1,937.0 | 17.2 | -102.1 | -363.1 | -19 | -- | 3.2 | |
| 16.9 | 1,115.4 | 321.1 | 2.4 | 1,727.2 | 1.1 | 400.3 | 3.9 | |
| 3.4 | 568.7 | 4.6 | -201.1 | -4,342.4 | -146.8 | -- | 5.3 | |
| 6.3 | 913.1 | 174.7 | -115.2 | 0.0 | -80.2 | -- | 7.4 | |
| 20.3 | 2,015.9 | 460.2 | -175.5 | -37.7 | -22.6 | -- | 2.8 |
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and... LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts. Address: 6 Tide Street, Boston, MA, United States, 02210 Read more
Founder, Senior Advisor & Board Observer
Ms. Daphne Zohar
Founder, Senior Advisor & Board Observer
Ms. Daphne Zohar
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of PureTech Health PLC (PRTC) is $15.00 (NASDAQ) as of 01-Apr-2026 16:00 EDT. PureTech Health PLC (PRTC) has given a return of -19.72% in the last 3 years.
The P/E ratio of PureTech Health PLC (PRTC) is 8.53 times as on 31-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
The 52-week high and low of PureTech Health PLC (PRTC) are Rs 20.00 and Rs 13.30 as of 02-Apr-2026.
PureTech Health PLC (PRTC) has a market capitalisation of $ 351 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in PureTech Health PLC (PRTC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.14
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.